Novartis Signs Licensing Deal Worth Up to $5.7 Billion with Monte Rosa Therapeutics

Deep News
Sep 15

Swiss pharmaceutical company Novartis AG (NYSE: NVS) and drug development firm Monte Rosa Therapeutics (NASDAQ: GLUE) announced on Monday a licensing agreement valued at up to $5.7 billion to jointly develop treatments for immune-mediated diseases.

Under the terms of the agreement, Monte Rosa Therapeutics will receive an upfront payment of $120 million. The company is also eligible to receive milestone payments and sales royalties that could total up to $5.7 billion if development targets are achieved and the resulting drugs reach commercial success.

This marks the second major partnership agreement Novartis has secured this month. The company previously entered into a deal worth up to $5.2 billion with Chinese biotechnology firm Argo Biopharmaceutical to co-develop experimental treatments for heart diseases.

Following the announcement, Monte Rosa Therapeutics' shares surged 50% in pre-market trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10